NASDAQ, CBLI - Cleveland Biolabs
CBLI was incorporated in Delaware and commenced business operations in June 2003
as a development-stage, biotechnology company, with a very specific and targeted
focus on radiation drug discovery. We have devoted substantially all of our
resources to the identification, development and commercialization of new types
of drugs for protection of normal tissues from exposure to radiation and other
stresses, such as toxic chemicals and cancer treatments. CBLI?s pipeline
includes products from two primary families of compounds: protectans and
curaxins. We are developing protectans as drug candidates that protect healthy
tissues from acute stresses such as radiation, chemotherapy and ischemia
(pathologies developed as a result of blocking blood flow to a part of the
body). Curaxins are being developed as anticancer agents that could act as
mono-therapy drugs or in combination with other existing anticancer agents. ...
Read SEC Filing on NASDAQ.com »